International Journal of Stem Cells : eISSN 2005-5447

Fig. 4.

Download original image
Fig. 4. MiR-34c-5p decreased cell activity and increased ALP content of BMSCs by inhibiting Bcl-2 expression. (A) The binding site of miR-34c-5p and Bcl-2 was predicted by TargetScan. (B, C) Dual-luciferase reporter gene assay was used to verify the targeted binding relationship between miR-34c-5p and Bcl-2. (D) The cell proliferation of BMSCs transfected with or untransfected miR-34c-5p mimic and/or Bcl-2 was detected by CCK-8 at 1, 3, 5 and 7 day. (E) The cell proliferation of BMSCs treated or untreated with miR-34c-5p inhibitor and/or siBcl-2 was detected by CCK-8 at 1, 3, 5 and 7 day. (F) The ALP content of BMSCs treated or untreated with miR-34c-5p mimic and/or Bcl-2 was detected by ELISA. (G) The ALP content of BMSCs treated or untreated with miR-34c-5p inhibitor and/or siBcl-2 was detected by ELISA. *vs. MC, #vs. M, vs. BCL2, ^vs. IC, §vs. I, vs. siBCL2. or ^ or or §p<0.05; ## or ^^ or §§p<0.01; *** or ^^^ or ††† or ###p<0.001. BMSCs, bone marrow mesenchymal stem cells; CCK-8, cell counting 8; ALP, alkaline phosphatase; ELISA, enzyme linked immune sorbent assay; Bcl-2, B cell lymphoma/lewkmia-2; I, miR-34c-5p inhibitor; IC, inhibitor control; M, miR-34c-5p mimic; MC, mimic control. The experiment was independently repeated three times.
International Journal of Stem Cells 2021;14:286-97 https://doi.org/10.15283/ijsc20188
© 2021 International Journal of Stem Cells